SUPPORTING INFORMATION

Figure S1. (A) Initial hits were classified into three classes: antifungals, antibacterials, and antivirals. (B) Venn diagram showing initial hits active against either or both *C. albicans* SC5314 and *C. auris* 0390



	Everolimus	MMV1633966	MMV1593537
MMV ID	639951	1633966	1593537
STRUCTURE			
CHEMICAL NAME	rac (1S,9R,12R,15S,16E,18S,19S,21S,23R,24E,26E,28E,3 0R,32R,35S)-1,18-dihydroxy-19,30-dimethoxy- 15,17,21,23,29,35-hexamethyl-12-[rac-(2S)-1-[rac- (1R,3S,4S)-4-(2-hydroxyethoxy)-3- methoxycyclohexyl]propan-2-yl]-11,36-dioxa-4- azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28- tetraene-2,3,10,14,20-pentone	1-[2-[(2,10-dichloro-5,7- dihydroindolo[2,3- b]carbazol-6- yl)oxy]ethyl]tetrazol-5- amine	3-[4,5-bis(4- fluorophenyl)-1H- imidazol-2-yl]-5-bromo- 1H-indole
FORMULA	C ₅₃ H ₈₃ N O ₁₄	C ₂₁ H ₁₅ Cl ₂ N ₇ O	C ₂₃ H ₁₄ Br F ₂ N ₃
MOLECULAR			
WEIGHT (DA)	958.2	452.3	450.3
DISEASE AREA	Antivirals	Antibacterials	Antibacterials

Table S1. Structure and chemical information of the leading repositionable compounds everolimus, MMV1633966 and MMV1593537.

Table S2. MIC values of MMV1633966 and MMV1593537 after exposure to planktonic forms of medically important yeast and filamentous fungi. FLZ, fluconazole; VRZ, voriconazole; PSZ, Posaconazole.

Species/FTL	MMV1633966		MMV1593537		FLZ	VRZ	PSZ
number	50%	100%	50%	100%	50%	100%	100%
C. parapsilosis							
ATCC22019	1	2	2	2	1		
C.albicans							
ATCC 90028	1	1	2	2	≤0.125		
C. auris							
Cau-1	1	1	2	2	>64		
C. glabrata							
Cg-2	1	1	2	2	4		
Cr. neoformans							
Crn-2	1	>16	2	2	4		
P. variotii.							
MYA-3630							
Rhizopus sp.							
Rh-1	>16	>16	>16	>16			1
A. fumigatus							
AF293	>16	>16	16	>16		0.5	
Fusarium sp							
Fs-3	>16	>16	>16	>16		>16	

Figure S2. Cytotoxicities of the MMV1633966 (MMV1) and MMV1593537 (MMV2) compounds. Cytotoxicity was measured using a human hepatocellular carcinoma (HepG2) cell line. For each compound, the concentration that reduced cell viability by 50% (CC₅₀) was calculated based on these assays.





Figure S3. Activity of everolimus against different clinical isolates of *C. auris* under planktonic growth conditions.



Figure S4. Inhibition of biofilm formation by different clinical isolates of *C. auris* by everolimus.



Figure S5. Activity of everolimus against mature biofilms formed by different clinical isolates of *C. auris.*